Theralase Technologies Inc.

Theralase Technologies Inc.

February 28, 2011 09:01 ET

Theralase Cancer Therapy Trials Prove Safety of Patented Compounds

TORONTO, ONTARIO--(Marketwire - Feb. 28, 2011) - Theralase Technologies Inc. (TSX VENTURE:TLT) announced today that it has successfully completed the pre-clinical safety testing in an in vivo mouse model, the next step in the commercialization of its innovative Photo Dynamic Compound (PDC) platform technology. The Theralase patented PDC's comprise a family of novel drug candidates under evaluation from the company's proprietary PDC inventory focused on oncological indications.

Lothar Lilge Ph.D., the principal investigator of the Theralase PDC cancer compound technology at the Ontario Cancer Institute of the renowned Princess Margaret Hospital, University Health Network stated that, "For the four lead PDCs under investigation the Mean Tolerated Dose (MTD) was determined in an established in-vivo pre-clinical safety model and was well tolerated by animals at levels comparable to and above that of other FDA approved photosensitizers. Results demonstrate that the observed MTD was ten times higher than clinical doses of photosensitizers currently employed in medical practice. This provides the basis of a strong safety and tolerability profile of the patented Theralase PDCs. It also provides the required data to allow our research to proceed to the next stage; specifically, the determination of the effectiveness of the Theralase PDCs in the selective destruction of cancerous tumours growth and metastatic spread, while preserving normal tissue. We will also evaluate skin photosensitivity and the tissue selectivity of the PDCs to cancer versus normal tissue structures during treatment. I am encouraged by the results achieved to date and my team looks forward to establishing the efficacy of the Theralase PDCs in these established cancer models, as our research progresses."

Roger Dumoulin-White, President and CEO of Theralase Inc. stated that, "We are delighted that our research into these cancer killing PDCs has progressed to where we can introduce them safely and tolerably at very high doses into live animals. This is the crucial step in evaluating Theralase's anti-cancer technology in an in vivo preclinical MTD model that lays the groundwork for proving the application of the first generation of Theralase's patented platform technology for advanced anti-cancer therapy. If proven successful in the next set of animal preclinical cancer models, we will be able to undertake early discussions with the FDA and Health Canada on using our patented PDCs to destroy cancer in cats, dogs and horses, followed by the evaluation of the PDCs in human subjects in a Phase I human clinical trial.

Visit the corporate or regulatory website at or for more information.

About Theralase Technologies Inc.

Theralase Technologies Inc. designs, develops and manufactures patented, super-pulsed laser technology utilized in bio-stimulation and bio-destruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound care. When combined with patented light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria and viruses. 

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

Contact Information